Acne Vulgaris, Male and Female Pattern Hair Loss, Telogen Effluvium, and Alopecia Areata: A Complete Clinical Guide

What Is Acne Vulgaris and What Causes It?

Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit, driven by four intersecting mechanisms: excess sebum production, follicular hyperkeratinization, colonization by Cutibacterium acnes (formerly Propionibacterium acnes), and the resulting inflammatory cascade. It is not a single pimple. It is a spectrum ranging from non-inflammatory comedones to deep, scarring nodulocystic lesions.

Androgens, particularly dihydrotestosterone (DHT) and dehydroepiandrosterone sulfate (DHEAS), stimulate sebaceous gland activity. This is why acne surges at puberty and why women often flare premenstrually when progesterone peaks. A 2019 Global Burden of Disease analysis estimated that acne affected approximately 654 million people worldwide, making it the eighth most common disease globally. [1]

Genetics also matter. If both parents had severe acne, a child's risk of developing the same is roughly four times higher than the population baseline. Diet may contribute too: a 2020 systematic review in the Journal of the Academy of Nutrition and Dietetics found associations between high-glycemic-load diets and acne severity, though the effect size was modest and causation remains unproven. [2]

Grades of acne loosely map to treatment intensity:

• Grade I (comedonal): open and closed comedones, no papules
• Grade II (mild-moderate): comedones plus scattered papules and pustules
• Grade III (moderate-severe): numerous papules, pustules, and nodules
• Grade IV (nodulocystic/conglobate): deep, interconnected nodules with a high scarring risk

FDA-Approved and Guideline-Recommended Acne Treatments

Topical retinoids are the backbone of most acne regimens. Tretinoin 0.025-0.1% cream or gel normalizes follicular keratinization, prevents new comedone formation, and reduces post-inflammatory hyperpigmentation. The 2016 American Academy of Dermatology (AAD) acne guidelines state: "Topical retinoids are recommended for almost all acne patients because of their comedolytic and anti-inflammatory properties." [3]

Benzoyl peroxide (BPO) at concentrations of 2.5-10% kills C. acnes via oxidative stress and, critically, does not induce antibiotic resistance. Combining BPO with a topical antibiotic (clindamycin 1% or erythromycin 2%) is standard of care for moderate acne precisely because BPO suppresses the selection of resistant strains. [3]

Oral antibiotics, mainly doxycycline 50-100 mg twice daily or minocycline 45-135 mg once daily (the modified-release formulation), are used for moderate-to-severe inflammatory acne. The AAD guidelines recommend limiting antibiotic courses to 3-6 months to reduce resistance pressure. [3]

For severe nodulocystic acne, oral isotretinoin remains the most effective single agent available. A cumulative dose of 120-150 mg/kg over 16-24 weeks produces sustained remission in approximately 85% of patients after one course. [4] Isotretinoin requires enrollment in the iPLEDGE REMS program in the United States because of its teratogenicity. Two negative pregnancy tests 30 days apart are required before treatment starts in patients with child-bearing potential. [5]

Hormonal therapies address the androgen component. Spironolactone 25-200 mg/day is used off-label in women with hormonal acne (typically perimenstrual flares, jawline and chin distribution). Combined oral contraceptives containing ethinyl estradiol with norgestimate, norethindrone acetate, or drospirenone carry FDA approval specifically for acne in women. A 2012 Cochrane review of 31 trials confirmed that combined OCs reduce inflammatory and non-inflammatory acne lesion counts compared with placebo. [6]

Male Pattern Hair Loss (Androgenetic Alopecia in Men)

Male pattern hair loss (MPHL), or androgenetic alopecia (AGA), affects roughly 50% of men by age 50 and up to 80% by age 70. [7] The hallmark is progressive miniaturization of genetically susceptible hair follicles driven by DHT binding to androgen receptors in the dermal papilla. DHT is formed from testosterone by the enzyme 5-alpha reductase type II, which is concentrated in scalp follicles. The result is a shortened anagen (growth) phase, increasingly fine vellus-like hair, and eventual follicle dropout.

The Hamilton-Norwood scale classifies MPHL into seven stages, from a symmetric hairline recession at the temples (Stage II) through complete vertex balding with only a peripheral rim remaining (Stage VII).

Finasteride 1 mg/day is the primary oral treatment. It inhibits 5-alpha reductase type II, reducing scalp DHT by approximately 60%. The key Phase III trial published in the Journal of the American Academy of Dermatology (N=1,553 to 12 months) showed that finasteride 1 mg/day increased hair count by a mean of 107 hairs per cm² versus a decrease of 75 hairs per cm² in the placebo group. [8] Sexual side effects (decreased libido, erectile dysfunction) occur in roughly 1.5-2% of men; they resolve in most patients after discontinuation. Patients should be counseled that finasteride suppresses PSA levels by approximately 50%, which must be accounted for when interpreting prostate cancer screening results.

Topical minoxidil 5% solution or foam applied once or twice daily is the other FDA-approved option. Its exact mechanism is not fully established, but minoxidil prolongs the anagen phase and increases follicular size. In a 12-month double-blind trial (N=393), topical minoxidil 5% solution produced a mean increase of 18.6 target area hairs versus 7.9 with 2% solution at 48 weeks. [9]

Oral minoxidil at low doses (0.625-2.5 mg/day) has gained clinical traction as an off-label alternative. A randomized controlled trial published in the Journal of the American Academy of Dermatology in 2022 found that oral minoxidil 5 mg/day produced significantly greater hair density increases compared with topical minoxidil 5% at 24 weeks in men with AGA. [10] The most common side effect at low doses is fine facial or body hypertrichosis.

Hair transplantation (follicular unit excision or strip harvesting) is a surgical option for men with stable, advanced MPHL. Transplanted follicles retain their genetic resistance to DHT and are permanent, but medical therapy is still recommended post-transplant to slow progression in untransplanted areas.

Female Pattern Hair Loss (Androgenetic Alopecia in Women)

Female pattern hair loss (FPHL) follows a different distribution from MPHL. Women typically show diffuse thinning over the crown and a widening central part, which the Ludwig scale classifies into three grades. Frontal hairline is generally preserved, which is a useful clinical distinguishing feature from telogen effluvium.

FPHL affects roughly 12% of women by age 29 and climbs to approximately 40% by age 70. [11] Serum androgen levels are often normal in FPHL, suggesting that follicular androgen-receptor sensitivity, not androgen excess, is the dominant driver in many cases.

Topical minoxidil 2% or 5% is the only FDA-approved topical treatment for women. The 2% solution twice daily has more safety data; the 5% foam once daily is approved as well and may offer better adherence. A 48-week RCT (N=381) demonstrated that minoxidil 5% foam once daily was non-inferior to 2% solution twice daily in women. [12]

Spironolactone 25-200 mg/day is widely used off-label and is supported by the 2018 British Association of Dermatologists guidelines as a reasonable second-line agent in women with FPHL, particularly those with elevated androgens or associated acne. [13] It acts as an androgen-receptor antagonist and weak 5-alpha reductase inhibitor. Potassium levels should be monitored, especially if the patient is taking ACE inhibitors or ARBs.

Finasteride is used off-label in post-menopausal women at 1-5 mg/day. It is contraindicated in women of child-bearing potential because of teratogenicity (Type X in pregnancy).

Low-level laser therapy (LLLT) devices cleared by the FDA as medical devices may modestly increase hair density in FPHL. A 2014 RCT (N=128) showed a 51% increase in hair density with a 26-beam laser device versus 11% with sham. [14]

A practical decision framework for new FPHL patients at HealthRX: obtain a TSH, serum ferritin (target >40 ng/mL), total and free testosterone, DHEAS, and prolactin before initiating pharmacotherapy. Iron deficiency with ferritin <30 ng/mL is a correctable contributor and should be treated concurrently. Nutritional deficiencies, particularly zinc and vitamin D, are also worth addressing, though evidence for supplementation as monotherapy is limited.

Telogen Effluvium: Temporary but Distressing Shedding

Telogen effluvium (TE) occurs when a physiological or psychological stressor prematurely pushes a large proportion of anagen follicles into the telogen (resting) phase. Six to sixteen weeks later, those hairs shed simultaneously. A person may lose 200-400 hairs per day at peak shedding versus the normal baseline of roughly 50-100. [15]

Common triggers include:

• Childbirth (postpartum TE is the most prevalent form)
• Major surgery or general anesthesia
• Febrile illnesses, including COVID-19
• Thyroid dysfunction (both hyper- and hypothyroidism)
• Crash dieting or caloric restriction below approximately 1,000 kcal/day
• Abrupt discontinuation of combined oral contraceptives
• Significant psychological stress

The hair pull test is a quick bedside diagnostic: grasping 40-60 hairs near the scalp and pulling gently; extracting more than 6 telogen hairs (club-shaped white bulb) is a positive result. Trichoscopy showing a diffuse decrease in hair shaft caliber without miniaturization helps distinguish TE from AGA. A scalp biopsy in TE shows a telogen-to-anagen ratio above 25%, compared with a normal 10-15%.

TE typically self-resolves within 3-6 months once the trigger is identified and corrected. No pharmacotherapy is required in most cases. If shedding persists beyond 6 months (chronic TE), reassessment for an underlying systemic cause, occult thyroid disease, or iron deficiency is warranted. Topical minoxidil may accelerate regrowth in prolonged cases, though published RCT evidence specifically in chronic TE is limited.

Alopecia Areata: Autoimmune Follicle Attack

Alopecia areata (AA) is an organ-specific autoimmune disease in which T lymphocytes collapse the immune privilege of hair follicles, triggering a CD8+ T-cell attack on anagen-phase follicles. The result is sudden, discrete, non-scarring patches of hair loss. Lifetime prevalence is approximately 2% of the general population. [16]

The clinical spectrum ranges from single patches (alopecia areata patchy) to complete scalp hair loss (alopecia totalis) and loss of all body hair (alopecia universalis). Nail pitting is present in 10-20% of AA patients and can aid diagnosis.

Intralesional corticosteroids remain first-line for patchy AA affecting <50% of the scalp. Triamcinolone acetonide 2.5-10 mg/mL injected in 0.1 mL aliquots across the affected area every 4-6 weeks produces regrowth in 60-70% of patchy AA cases. [17] Repeated injections carry a risk of local skin atrophy; depth and volume per injection site should be carefully controlled.

Topical corticosteroids and topical minoxidil are adjunct options with modest independent evidence. High-potency topical steroids (clobetasol propionate 0.05%) under occlusion may help smaller patches in patients who cannot tolerate injections.

JAK inhibitors represent a major advance. Baricitinib 2 mg and 4 mg/day (Olumiant) received FDA approval in June 2022 specifically for severe alopecia areata, the first systemic treatment to receive this indication. [18] The BRAVE-AA1 trial (N=654) showed that 38.8% of patients on baricitinib 4 mg/day achieved a SALT score of 20 or below (meaning at least 80% scalp coverage) at 36 weeks, versus 3% on placebo. [19] Ritlecitinib 50 mg/day (Litfulo) was approved by the FDA in June 2023 for patients aged 12 and older with severe AA. [20]

These JAK inhibitors block JAK1/JAK2 or JAK3/TEC pathways, interrupting the interferon-gamma signaling that sustains follicular autoimmune attack. The FDA class labeling carries a black-box warning for serious infections, malignancies, and major adverse cardiovascular events; baseline laboratory screening (CBC, lipids, hepatic function, TB testing) is required before initiation.

How Acne and Hair Loss Can Overlap

The connection between acne and hair loss is not coincidental. Both FPHL and hormonal acne share androgenic roots. Women with polycystic ovary syndrome (PCOS) frequently present with all three: acne, FPHL, and hirsutism, driven by hyperandrogenism. PCOS affects an estimated 6-12% of US women of reproductive age, per CDC data. [21]

Spironolactone, as noted above, addresses both acne and FPHL in women. A single prescription can treat two conditions simultaneously, which improves adherence. Similarly, isotretinoin causes hair thinning in roughly 10% of patients during the treatment course, a drug-induced telogen effluvium that typically reverses after the course ends.

Scalp acne (acne necrotica, folliculitis decalvans in its severe form) is a distinct entity that can cause permanent hair loss if untreated. Folliculitis decalvans responds to rifampicin 300 mg twice daily combined with clindamycin 300 mg twice daily for 10 weeks, a regimen supported by observational data at major dermatology centers. [22]

Acne Scarring: Preventing and Treating Permanent Skin Damage

Acne scars form when deep inflammation disrupts dermal collagen. Ice-pick scars, rolling scars, and boxcar scars are the three morphologic subtypes. Prevention is the most cost-effective strategy: starting effective treatment early (within 6-8 weeks of developing moderate acne) meaningfully reduces scarring risk. A 2018 retrospective cohort of 800 patients showed that patients who waited more than 3 years from acne onset to initiate treatment were 4.8 times more likely to have permanent scarring. [23]

Treatment options for established scars include:

• Subcision for tethered rolling scars, releasing fibrotic attachments under the skin
• Fractional CO2 laser for ice-pick and boxcar scars; typically 3-5 sessions at 4-6 week intervals
• Chemical reconstruction of skin scars (CROSS) with 65-100% trichloroacetic acid for deep ice-pick scars
• Microneedling with or without platelet-rich plasma for mild-to-moderate rolling scars

No single modality works for all scar types. A combination approach tailored to scar morphology produces the best outcomes.

When to Escalate Care and What to Ask Your Provider

Some clinical signs warrant prompt evaluation rather than watchful waiting:

• Acne that fails to improve after 3 months of topical therapy
• Hair loss exceeding 200 hairs/day beyond 6 months
• Patchy hair loss with an expanding scalp bald surface area
• Systemic symptoms accompanying hair loss: fatigue, weight change, cold intolerance
• A SALT score deteriorating despite ongoing topical treatment for AA

A board-certified dermatologist can perform trichoscopy, trichogram, or scalp biopsy to establish a precise diagnosis. Telehealth platforms like HealthRX can manage mild-to-moderate acne, FPHL on minoxidil or spironolactone, and early AGA confidently with asynchronous photo review and same-week prescriptions, but patients with suspected autoimmune conditions or nodulocystic acne requiring isotretinoin benefit from synchronous consultation.

The AAD 2024 position statement on teledermatology notes that photographic diagnosis of acne and androgenetic alopecia has a diagnostic concordance rate of approximately 87% with in-person evaluation, supporting telehealth as a valid first-contact model for these conditions. [24]